Moderna (Moderna) Change In Receivables : $976 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Moderna Change In Receivables?

Moderna's change in receivables for the quarter that ended in Mar. 2024 was $755 Mil. It means Moderna's Accounts Receivable declined by $755 Mil from Dec. 2023 to Mar. 2024 .

Moderna's change in receivables for the fiscal year that ended in Dec. 2023 was $493 Mil. It means Moderna's Accounts Receivable declined by $493 Mil from Dec. 2022 to Dec. 2023 .

Moderna's Accounts Receivable for the quarter that ended in Mar. 2024 was $137 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Moderna's Days Sales Outstanding for the three months ended in Mar. 2024 was 74.86.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Moderna's liquidation value for the three months ended in Mar. 2024 was $4,861 Mil.

Moderna Change In Receivables Historical Data

The historical data trend for Moderna's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Change In Receivables Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

7.00

-1,385.00

-1,784.00

1,790.00

493.00

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															272.00	881.00	-1,634.00	974.00	755.00

Moderna Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $976 Mil.

Moderna (NAS:MRNA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Moderna's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	137	/	167	*	91
=	74.86

2. In Ben Graham's calculation of liquidation value, Moderna's accounts receivable are only considered to be worth 75% of book value:

Moderna's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8523	-	3912	+	0.75 * 137	+	0.5 * 295
=	4,861

Moderna Change In Receivables Related Terms

Thank you for viewing the detailed overview of Moderna's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (Moderna) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany 0QF:Germany 0QF:Germany 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Executives

Stephen Hoge	officer: President	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock	officer: Chief Financial Officer	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger	officer: Chief Legal Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay	officer: Chief Commercial Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel	director, officer: Chief Executive Officer	320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres	officer: See Remarks	C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton	officer: Chief Medical Officer	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline	officer: Chief Financial Officer	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez	officer: See Remarks	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan	director	AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson	officer: General Counsel and Secretary	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne	officer: Chief Commercial Officer	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115